Poor Efficacy of L-Acetylcarnitine in the Treatment of Asthenozoospermia in Patients with Type 1 Diabetes
Abstract
1. Introduction
2. Patients and Methods
3. Sperm Analysis
4. Measurement of Serum Hormone Concentrations
5. Statistical Analysis
6. Results
7. Discussion
8. Study Limitations
Author Contributions
Conflicts of Interest
References
- La Vignera, S.; Condorelli, R.; Vicari, E.; D’Agata, R. Calogero AE. Diabetes mellitus and sperm parameters. J. Androl. 2012, 33, 145–153. [Google Scholar] [CrossRef]
- Condorelli, R.A.; Calogero, A.E.; Vicari, E.; Duca, Y.; Favilla, V.; Morgia, G.; Cimino, S.; Di Mauro, M.; La Vignera, S. Prevalence of male accessory gland inflammations/infections in patients with Type 2 diabetes mellitus. J. Endocrinol. Invest. 2013, 36, 770–774. [Google Scholar]
- Condorelli, R.A.; Vicari, E.; Calogero, A.E.; La Vignera, S. Male accessory gland inflammation prevalence in type 2 diabetic patients with symptoms possibly reflecting autonomic neuropathy. Asian J. Androl. 2014, 16, 761–766. [Google Scholar] [PubMed]
- La Vignera, S.; Condorelli, R.A.; Vicari, E.; D’Agata, R.; Salemi, M.; Calogero, A.E. High levels of lipid peroxidation in semen of diabetic patients. Andrologia 2012, 44, 565–570. [Google Scholar] [CrossRef] [PubMed]
- Condorelli, R.A.; La Vignera, S.; Mongioì, L.M.; Alamo, A.; Calogero, A.E. Diabetes Mellitus and Infertility: Different Pathophysiological Effects in Type 1 and Type 2 on Sperm Function. Front. Endocrinol. (Lausanne). 2018, 9, 268. [Google Scholar] [CrossRef]
- La Vignera, S.; Condorelli, R.A.; Di Mauro, M.; Lo Presti, D.; Mongioì, L.M.; Russo, G.; Calogero, A.E. Reproductive function in male patients with type 1 diabetes mellitus. Andrology 2015, 3, 1082–1087. [Google Scholar] [CrossRef] [PubMed]
- Pergialiotis, V.; Prodromidou, A.; Frountzas, M.; Korou, L.M.; Vlachos, G.D.; Perrea, D. Diabetes mellitus and functional sperm characteristics: A meta-analysis of observational studies. J. Diabetes Complications. 2016, 30, 1167–1176. [Google Scholar] [CrossRef] [PubMed]
- Mongioi’, L.; Calogero, A.E.; Vicari, E.; Condorelli, R.A.; Russo, G.I.; Privitera, S.; Morgia, G.; La Vignera, S. The role of carnitine in male infertility. Andrology 2016, 4, 800–807. [Google Scholar] [CrossRef]
- Omar, M.I.; Pal, R.P.; Kelly, B.D.; Bruins, H.M.; Yuan, Y.; Diemer, T.; Krausz, C.; Tournaye, H.; Kopa, Z.; Jungwirth, A.; et al. Benefits of Empiric Nutritional and Medical Therapy for Semen Parameters and Pregnancy and Live Birth Rates in Couples with Idiopathic Infertility: A Systematic Review and Meta-analysis. Eur. Urol. 2019, 75, 615–625. [Google Scholar] [CrossRef] [PubMed]
- Coker, M.; Coker, C.; Darcan, S.; Can, S.; Orbak, Z.; Gökşen, D. Carnitine metabolism in diabetes mellitus. J. Pediatr. Endocrinol. Metab. 2002, 15, 841–849. [Google Scholar] [CrossRef] [PubMed]
- La Marca, G.; Malvagia, S.; Toni, S.; Piccini, B.; Di Ciommo, V.; Bottazzo, G.F. Children who develop type 1 diabetes early in life show low levels of carnitine and amino acids at birth: Does this finding shed light on the etiopathogenesis of the disease? Nutr. Diabetes. 2013, 28, e94. [Google Scholar] [CrossRef] [PubMed]
- Mamoulakis, D.; Galanakis, E.; Dionyssopoulou, E.; Evangeliou, A.; Sbyrakis, S. Carnitine deficiency in children and adolescents with type 1 diabetes. J. Diabetes Complications. 2004, 18, 271–274. [Google Scholar] [CrossRef]
- Agarwal, A.; Said, T.M. Carnitines and male infertility. Reprod. Biomed. Online 2004, 8, 376–384. [Google Scholar] [CrossRef]
- Lenzi, A.; Lombardo, F.; Gandini, L.; Dondero, F. Metabolism and action of L-carnitine: Its possible role in sperm tail function. Arch. Ital. Urol. Nefrol. Androl. 1992, 64, 187–196. [Google Scholar]
- Ng, C.M.; Blackman, M.R.; Wang, C.; Swerdloff, R.S. The role of carnitine in the male reproductive system. Ann. N.Y. Acad. Sci. 2004, 1033, 177–188. [Google Scholar] [CrossRef] [PubMed]
- Vidal-Casariego, A.; Burgos-Peláez, R.; Martínez-Faedo, C.; Calvo-Gracia, F.; Valero-Zanuy, M.Á.; Luengo-Pérez, L.M.; Cuerda-Compés, C. Metabolic effects of L-carnitine on type 2 diabetes mellitus: Systematic review and meta-analysis. Exp. Clin. Endocrinol. Diabetes. 2013, 121, 234–238. [Google Scholar] [CrossRef] [PubMed]
- Evans, J.D.; Jacobs, T.F.; Evans, E.W. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann. Pharmacother. 2008, 42, 1686–1691. [Google Scholar] [CrossRef]
- Moncada, M.L.; Vicari, E.; Cimino, C.; Calogero, A.E.; Mongioì, A.; D’Agata, R. Effect of acetylcarnitine treatment in oligoasthenospermic patients. Acta. Eur. Fertil. 1992, 23, 221–224. [Google Scholar]
- Costa, M.; Canale, D.; Filicori, M.; D’lddio, S.; Lenzi, A. L-carnitine in idiopathic asthenozoospermia: A multicenter study. Italian Study Group on Carnitine and Male Infertility. Andrologia 1994, 26, 155–159. [Google Scholar] [CrossRef] [PubMed]
- Vitali, G.; Parente, R.; Melotti, C. Carnitine supplementation in human idiopathic asthenospermia: Clinical results. Drugs Exp. Clin. Res. 1995, 21, 157–159. [Google Scholar]
- Balercia, G.; Regoli, F.; Armeni, T.; Koverech, A.; Mantero, F.; Boscaro, M. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertil. Steril. 2005, 84, 662–671. [Google Scholar] [CrossRef] [PubMed]
- Ring, J.D.; Lwin, A.A.; Köhler, T.S. Current medical management of endocrine-related male infertility. Asian J. Androl. 2016, 18, 357–363. [Google Scholar] [CrossRef] [PubMed]
Parameters | Group A (n = 20) | Group B (n = 20) | p-value |
---|---|---|---|
Anthropometric parameters | |||
Age (years), median (IQR) | 25.0 (22.0–33.0) | 27.0 (24.0–35.0) | 0.30 |
Weight (kg), median (IQR) | 69.0 (64.5–76.5) | 71.0 (60.5–77.0) | 0.69 |
Height (m), median (IQR) | 176.0 (170.0–179.0) | 174.5 (168.5–178.0) | 0.30 |
Body mass index (kg/m2), median (IQR) | 23.0 (21.25–24.75) | 24.0 (22.25–29.75) | 0.30 |
Waist circumference (cm), median (IQR) | 86.0 (81.25–88.0) | 88.0 (82.0–90.0) | 0.25 |
Sperm parameters | |||
Volume (mL), median (IQR) | 1.8 (1.6–3.0) | 1.9 (1.6–3.2) | 0.97 |
Concentration (mil/mL), median (IQR) | 25.0 (20.0–45.0) | 28.0 (22.0–50.0) | 0.26 |
Progressive motility (%), median (IQR) | 8.0 (2.0–12.0) | 7.0 (3.0–15.0) | 0.69 |
Normal forms (%), median (IQR) | 8.0 (6.0–14.0) | 7.0 (5.0–15.0) | 0.72 |
Leucocytes (mil/mL), median (IQR) | 0.4 (0.30–0.80) | 0.5 (0.2–0.8) | 0.96 |
Hormonal parameters | |||
LH (UI/L), median (IQR) | 2.3 (1.72–2.57) | 2.1 (0.8–2.55) | 0.22 |
FSH (UI/L), median (IQR) | 2.9 (2.50–3.50) | 2.6 (0.32–3.3) | 0.30 |
TT (ng/mL), median (IQR) | 6.2 (5.0–8.2) | 6.4 (4.8–8.2) | 0.30 |
E2 (pg/mL), median (IQR) | 9.0 (6.25–11.5) | 8.6 (5.0–13.75) | 0.24 |
PRL (ng/mL), median (IQR) | 10.5 (7.25–12.75) | 12.0 (6.0–16.0) | 0.26 |
Parameter | Group Aat Enrollment | Group Aafter Treatment | Group Bat Enrollment | Group Bafter Treatment |
---|---|---|---|---|
Volume (mL), median (IQR) | 1.8 (1.6–3.0) | 2.0 (1.5–3.2) | 1.9 (1.6–3.2) | 2.3 (1.5–3.5) |
Concentration (mil/mL), median (IQR) | 25.0 (20.0–45.0) | 29.0 (22.0–49.0) | 28.0 (22.0–50.0) | 32.0 (24.0–51.0) |
Progressive motility (%), median (IQR) | 8.0 (2.0–12.00) | 9.0 (2.0–14.00) | 7.0 (3.0–15.00) | 20.0 * (5.0–28.00) |
Normal forms (%), median (IQR) | 8.0 (6.0–14.0) | 10.0 (7.0–16.0) | 7.0 (5.0–14.0) | 11.0 (7.0–18.0) |
Leucocytes (mil/mL), median (IQR) | 0.4 (0.3–0.8) | 0.5 (0.3–0.8) | 0.5 (0.2–0.8) | 0.3 (0.1–0.6) |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Condorelli, R.A.; Calogero, A.E.; Cannarella, R.; Giacone, F.; Mongioi’, L.M.; Cimino, L.; Aversa, A.; La Vignera, S. Poor Efficacy of L-Acetylcarnitine in the Treatment of Asthenozoospermia in Patients with Type 1 Diabetes. J. Clin. Med. 2019, 8, 585. https://doi.org/10.3390/jcm8050585
Condorelli RA, Calogero AE, Cannarella R, Giacone F, Mongioi’ LM, Cimino L, Aversa A, La Vignera S. Poor Efficacy of L-Acetylcarnitine in the Treatment of Asthenozoospermia in Patients with Type 1 Diabetes. Journal of Clinical Medicine. 2019; 8(5):585. https://doi.org/10.3390/jcm8050585
Chicago/Turabian StyleCondorelli, Rosita A., Aldo E. Calogero, Rossella Cannarella, Filippo Giacone, Laura M. Mongioi’, Laura Cimino, Antonio Aversa, and Sandro La Vignera. 2019. "Poor Efficacy of L-Acetylcarnitine in the Treatment of Asthenozoospermia in Patients with Type 1 Diabetes" Journal of Clinical Medicine 8, no. 5: 585. https://doi.org/10.3390/jcm8050585
APA StyleCondorelli, R. A., Calogero, A. E., Cannarella, R., Giacone, F., Mongioi’, L. M., Cimino, L., Aversa, A., & La Vignera, S. (2019). Poor Efficacy of L-Acetylcarnitine in the Treatment of Asthenozoospermia in Patients with Type 1 Diabetes. Journal of Clinical Medicine, 8(5), 585. https://doi.org/10.3390/jcm8050585